Loading clinical trials...
Loading clinical trials...
Epigenetic Regulation of Activity and Severity of Fibrous Dysplasia in Bone: mirDYS Study.
Fibrous dysplasia of bone is a rare congenital but non-hereditary disease caused by a post-zygotic activation mutation of the GNAS gene. Patients with fibrous dysplasia may present pain and bone complications (fractures, deformities..) related to their bone lesions. For undetermined reasons, severity and disease evolution may vary considerably from patient to patient. Epigenetic regulation could then be involved, including micro Ribonucleic Acids (miRs). These small non-coding micro Ribonucleic Acids are involved in the regulation of major steps of cellular processes in different pathologies, in particular in bone diseases. However, micro Ribonucleic Acids have never been studied in fibrous dysplasia. The aim of this study is to identify micro Ribonucleic Acids significantly associated with the severity of fibrous dysplasia.
Age
18 - No limit years
Sex
ALL
Healthy Volunteers
No
Service de Rhumatologie & INSERM U1033, Pavillon F, Hopital Edouard Herriot
Lyon, France
Start Date
January 10, 2019
Primary Completion Date
March 24, 2023
Completion Date
March 24, 2023
Last Updated
September 4, 2025
24
ACTUAL participants
Blood sample
OTHER
Waste bone tissue
OTHER
Lead Sponsor
Hospices Civils de Lyon
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions